Picture of Ion Beam Applications SA logo

IBAB — Ion Beam Applications SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

IBA falls on prudent guidance, short-term uncertainty despite FY beat

** Shares in Ion Beam Applications IBAB.BR fall nearly 10%, reversing course after rising around 4% in early trading, after the Belgian radiation therapy and radiopharmaceuticals equipment co announced a prudent 2025, mid-term guidance despite FY beat

** ING says 2025 REBIT guidance is on the "low side" and 2026 outlook "dropped"

** Co updated mid-term outlook, now sees 2024-28 revenue CAGR of 5-7%, c.10% REBIT margin by 2028; 2025 REBIT of at least 25 million euros ($27.13 million)

** "Management is more prudent on timing based on volatile order intake and current macro-economic context, which is in our view not reassuring," Degroof Petercam adds, 2025 REBIT guidance coming below its expectations

** ING fears higher short-term uncertainty may outweigh the reassuring long-term shift from the volatile PT case to lower-risk, higher-margin industrial/radio pharma accelerators

** "Management might simply play it safe here," the broker adds

** Shares are on track for their worst day in nearly nine months

($1 = 0.9216 euros)

 (Reporting by Olivier Cherfan)

 ((olivier.cherfan@thomsonreuters.com))

Recent news on Ion Beam Applications SA

See all news